InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results